Laboratory of Growth and Development (LabCreD), Center for Investigation in Pediatrics (CIPED), School of Medical Sciences (FCM), State University of Campinas (UNICAMP), 126 Tessália Vieira de Camargo Street, Cidade Universitária Zeferino Vaz, Campinas, SP, 13083-887, Brazil.
Laboratory of Investigation in Metabolism and Diabetes (LIMED), FCM, UNICAMP, Campinas, SP, Brazil.
Osteoporos Int. 2022 Jan;33(1):283-291. doi: 10.1007/s00198-021-06097-w. Epub 2021 Aug 18.
It is of great importance to investigate any potential detrimental effect on bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy. This study demonstrated normal bone health in well-controlled patients. Additionally, glucocorticoid dose may play an important role in the mineral density of femoral neck region.
To compare regional bone mineral densities (BMDs) and bone statuses of young adults with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase enzyme (21OHase) deficiency with a control group. The duration and dose of glucocorticoid therapy and relative skeletal muscle index (an indicator of sarcopenia) were also analyzed as parameters to predict bone health.
This case-control study included 23 patients (7 male and 16 female) and 20 controls (8 male and 12 female) matched by age range (18 to 31 years). Dual energy X-ray absorptiometry and phalangeal quantitative ultrasound (QUS) were used to estimate BMD and bone status, respectively.
No difference was observed between patients and controls (of both sexes) in absolute values of BMD and Z-scores for the total body, lumbar spine, and femoral neck; or the bone status (estimated by phalangeal QUS). Multiple linear regression analysis demonstrated that relative skeletal muscle index independently correlated with BMD of the entire body (β: 0.67, P = 0.007), the lumbar spine (β: 0.73, P = 0.005), and the femoral neck (β: 0.67, P = 0.007). However, the dose of glucocorticoids (β: - 0.38, P = 0.028) independently correlated with BMD in the femoral neck region alone.
No signs of change in bone health were observed in patients with CAH when compared to the reference group. Additionally, a marker of sarcopenia was demonstrated to have a role in mineral density mechanisms in all analyzed bone sites. Only the femoral neck BMD seemed to be significantly dependent on glucocorticoid dose.
比较因 21-羟化酶(21OHase)缺乏导致先天性肾上腺皮质增生症(CAH)的年轻成人与对照组的区域性骨矿物质密度(BMD)和骨骼状况。还分析了糖皮质激素治疗的持续时间和剂量以及相对骨骼肌指数(肌少症的一个指标)作为预测骨骼健康的参数。
本病例对照研究纳入了 23 名患者(7 名男性和 16 名女性)和 20 名对照者(8 名男性和 12 名女性),按年龄范围(18 至 31 岁)匹配。双能 X 线吸收法和指骨定量超声(QUS)分别用于估计 BMD 和骨骼状况。
患者和对照组(无论男女)在全身、腰椎和股骨颈的 BMD 绝对值和 Z 评分;或骨状态(通过指骨 QUS 评估)方面均无差异。多元线性回归分析表明,相对骨骼肌指数与全身(β:0.67,P=0.007)、腰椎(β:0.73,P=0.005)和股骨颈(β:0.67,P=0.007)的 BMD 独立相关。然而,糖皮质激素剂量(β:-0.38,P=0.028)仅与股骨颈 BMD 独立相关。
与参考组相比,CAH 患者的骨骼健康未见变化迹象。此外,肌少症的一个标志物被证明在所有分析的骨骼部位的矿物质密度机制中具有作用。只有股骨颈 BMD 似乎明显依赖于糖皮质激素剂量。